Genomic factors in prostate cancer among diverse men
Official title: Genomic and Genomic Variation in Prostate Cancer
Funded at Dana-Farber Cancer Inst · NIH-11535324 · Data updated 2026-11-12
A large NIH grant investigates how inherited genes and tumor DNA patterns influence the risk and behavior of prostate cancer, with a focus on diversity in African ancestry men.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 7, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $19,607 |
| NIH project number | 3R01CA259200-05S1 |
| Project ID | NIH-11535324 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with or at risk for prostate cancer, including those of African descent, who may contribute genetic and tumor samples for analysis.
✕Less likely to help
Results may not directly benefit individuals who do not participate or whose cancer biology does not align with the studied variants.
What this research studies
This project looks at how germline genetics and tumor genomics shape who gets prostate cancer and how aggressive it can be. Researchers will analyze genetic variants and tumor mutations to understand differences among men, especially those of African descent. The study aims to guide better, more accurate translation of genetic information into clinical care for American men with prostate cancer. By mapping genetic variation and tumor biology, the team hopes to improve risk assessment and potentially tailor treatments in the future.
Why it matters
Potential benefit: If successful, the work could lead to more accurate risk predictions and personalized treatment strategies for prostate cancer, particularly in men of African ancestry.
How similar studies have gone: Previous studies have shown that genetic and tumor genomics influence prostate cancer risk and progression, with ongoing exploration into diverse populations.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Rebbeck, Timothy Richard — Dana-Farber Cancer Inst
- Study coordinator: Rebbeck, Timothy Richard
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.